Idiopathic intracranial hypertension occurs throughout the world with an estimated incidence of one to three per 100,000 population per year. It occurs most commonly in obese young women but the cause is unknown. It presents a significant threat to sight and is associated with severe morbidity, in the form of headaches in most cases. Several different treatments have been proposed ranging from relatively conservative measures such as diuretic therapy to more invasive treatments such as optic nerve sheath fenestration, stenting of cerebral venous sinuses, or lumbo-peritoneal shunting.
The objective of this review was to assess the effects of various forms of treatment for idiopathic intracranial hypertension with a view to producing an evidence-based treatment strategy.
We searched the Cochrane Central Register of Controlled Trials (CENTRAL) (which contains the Cochrane Eyes and Vision Group Trials Register) (The Cochrane Library, Issue 4, 2008), MEDLINE (January 1950 to December 2008) and EMBASE (January 1980 to December 2008). There were no language or date restrictions in the search for trials. The electronic databases were last searched on 10 December 2008.
We included only randomised controlled trials in which any intervention used to treat idiopathic intracranial hypertension had been compared to placebo or to another form of treatment in people with a clinical diagnosis of idiopathic intracranial hypertension.
Data collection and analysis
Both authors independently assessed the search results for trials to be included in the review. Discrepancies were resolved by discussion. Since no trials met our inclusion criteria, no assessment of quality or meta-analysis was undertaken.
No randomised controlled trials were found that met the inclusion criteria.
There is insufficient information to generate an evidence-based management strategy for idiopathic intracranial hypertension. There is inadequate information regarding which treatments are truly beneficial and which are potentially harmful. Properly designed and executed trials are needed.
原發性顱內高壓在全世界的發生率約每年一萬人有一到三人.最常發生在肥胖的年輕女性,但原因不明.它造成視力明顯傷害並且並有嚴重的病態, 在大部分的病人以頭痛表現. 數個不同的治療已被提出,從相對保守的處置如利尿劑到較有侵襲性的治療如視神經鞘穿孔術(optic nerve sheath fenestration), 大腦靜脈竇(cerebral venous sinuses)的支架,或腰椎腹腔引流手術(lumboperitoneal shunting).
我們搜尋於Cochrane Library 的Cochrane Central Register of Controlled Trials (CENTRAL), 其中包含the Cochrane Eyes and Vision Group Trials Register(Issue 1, 2007), MEDLINE (1966 年至2007年一月) 和 EMBASE (1980年至2007年一月)及被選定的實驗報告的參考文獻.
此翻譯計畫由臺灣國家衛生研究院(National Health Research Institutes, Taiwan)統籌。
沒有足夠的證據關於治療原發性顱內高壓有效治療.原發性顱內高壓是沒有任何明顯原因造成腦內壓力增加的情況.這通常造成視神經盤(視神經與眼睛相遇處)的腫脹.至腫脹會造成可能的視力受損. 此現象最常發生於年輕肥胖的女性.有些治療已被提出. 此文獻並不能發現足夠的證據來指出最有效的治療方式.需要更多的研究.